Showing posts with label "robert t demarco". Show all posts
Showing posts with label "robert t demarco". Show all posts

Thursday, March 8, 2007

Exercise slows decline in Alzheimer's patients


I can attest, exercise makes a difference. My mother now has the tendency to sit around all day. On those days when I can get her to go to Gold's Gym with me she is a completely different person. The look on her face, from dull to smiling, is more than enough to tell me that exercise works to her benefit.

"Nursing home residents with Alzheimer's disease who participate in a moderate exercise program have a significantly slower deterioration than those who receive routine medical care, researchers have shown."

Read the article in its entirety at the CareGiver: The Book Weblog

Saturday, February 24, 2007

Study links seniors' loneliness to higher risk of dementia



Loneliness may put people at risk of an Alzheimer's-like dementia, a study reported Monday.
"People who described themselves as lonely were twice as likely to develop dementia," says researcher Robert Wilson of the Rush University Medical Center in Chicago.


Source USA Today

By Kathleen Fackelmann, USA TODAY

Loneliness may put people at risk of an Alzheimer's-like dementia, a study reported Monday.
"People who described themselves as lonely were twice as likely to develop dementia," says researcher Robert Wilson of the Rush University Medical Center in Chicago.

Other studies have found that people who are unmarried and socially isolated are at higher risk for dementia, including Alzheimer's. But this study is one of the first to show a link between loneliness — or the feelings of disconnection from other people — and a higher risk of developing dementia late in life, says Laurel Coleman, a spokeswoman for the Alzheimer's Association and a geriatrician in Portland, Maine.

Wilson and his colleagues studied 823 people who were about 80 years old and had no sign of dementia at the start of the study. The team gave the recruits a loneliness quiz and tested them annually for signs of memory loss and confusion, two key signs of dementia and Alzheimer's.

During the four-year study, 76 people developed an Alzheimer's-like dementia, Wilson says. The risk of developing dementia increased about 51% for each one-point increase on the loneliness scale. People with the highest scores had 2.1 times the risk of developing dementia, a group of conditions that destroy brain cells and lead to mental confusion. Alzheimer's is the most common form of dementia.

Autopsies were performed on 90 people who died during the study. The researchers found no link between loneliness and the development of the abnormal brain deposits that are the hallmark of Alzheimer's.

That finding suggests loneliness might be triggering dementia through a novel mechanism — one that doesn't lead to a brain riddled with deposits, Wilson says.

One theory is that people who are lonely over long periods of time might have higher levels of damaging stress hormones. The elevated stress hormones might lead to an accelerated aging of the brain — and perhaps to dementia, Wilson says.

Other research suggests lonely people are at risk of other health problems such as cancer and high blood pressure, says John Cacioppo of the University of Chicago. Still, he says, the new finding, which appears in February's Archives of General Psychiatry, must be verified by additional research.

The findings didn't change much when the team factored in markers of social isolation, such as infrequent participation in social events. That means that people who have a small number of good friends might be better off than those with a busy social schedule but chronic feelings of loneliness, Wilson says.

But lonely people often benefit from signing up for a new class or activity, Coleman says. Research shows that such activities might protect aging brain cells. And seniors who are out and about are more likely to make new friends, which might lessen feelings of loneliness, she says.




The CareGiver Blog
Robert T DeMarco
The Alzheimers Reading Room
AllAmerican Senior Care Weblog




Wednesday, February 21, 2007

New Drug Stops Alzheimer's In Tracks


The drug -- called Alzhemed -- attacks Amyloid Peptide - the molecule that causes Alzheimer's.

Paul Aisen, M.D.: "I think it is tremendously significant."

An early study showed Alzhemed stabilized the disease in nearly half of patients. Now, more than 1,000 are being followed.




Source ABC7


Nearly five-million Americans are living with Alzheimer's disease. Drugs on the market can treat the symptoms -- but not one goes after what causes it. Now, researchers are on the brink of a huge breakthrough with a drug that targets the cause and could stop the disease in its tracks.

Frances Goldstein: "I like to paint -- a lot."

Jacobo, her husband of 45 years, loves watching her mind at work. Frances has Alzheimer's disease -- diagnosed eight years ago at age 56.

Jacobo Goldstein, Wife has Alzheimer's: "For the first nine months, I couldn't tell her the word Alzheimer's because I was afraid, you know, that she might go into tremendous shock."

Instead, Frances fought back. For three years, she's been in a study testing a drug that could change her prognosis. Current Alzheimer's drugs target the symptoms of the disease...like memory loss and emotional problems. Well this new drug is taking a more direct approach.

Paul Aisen, M.D., Alzheimer's Specialist: "This drug is attacking the cause of Alzheimer's disease. If it works, it will change the course of the disease and that will represent a real breakthrough."

The drug -- called Alzhemed -- attacks Amyloid Peptide - the molecule that causes Alzheimer's. In mice, watch as the drug clears the molecule from the brain.

Paul Aisen, M.D.: "I think it is tremendously significant."

An early study showed Alzhemed stabilized the disease in nearly half of patients. Now, more than 1,000 are being followed.

Paul Aisen, M.D.: "If the phase three study confirms that the drug is effective, we will have a way of slowing the progression of Alzheimer's disease for the first time."

Frances takes Alzhemed twice a day.

Jacobo Goldstein: "I don't know where we would be if it wasn't for this. We have no idea. I know what she does now. If we can stay the way we are, we would be forever grateful."

With hope in hand, Frances continues to make every day and every painting count.

To date, more than 600 patients have completed one year of treatment on the medication. The study is scheduled to be complete soon. More than 70 centers across the United States and Canada are taking part. Side effects of the drug have been minimal and primarily include mild gastrointestinal symptoms.

Copyright 2007, ABC7/KGO-TV/DT.



Wednesday, February 7, 2007

Loneliness and Alzheimer's Linked


People who are lonely are twice as likely to develop Alzheimer's disease, a large US study has suggested.

Source Archives of General Psychiatry

A total of 823 older persons free of dementia at enrollment were recruited from senior citizen facilities in and around Chicago, Ill. Loneliness was assessed with a 5-item scale at baseline (mean ± SD, 2.3 ± 0.6) and annually thereafter. At death, a uniform postmortem examination of the brain was conducted to quantify AD pathology in multiple brain regions and the presence of cerebral infarctions.

The study found that the risk of Alzheimer's disease was more than doubled in lonely persons compared with persons who were not lonely. The study also concluded that Loneliness is associated with an increased risk of late-life dementia but not with its leading causes.



Sunday, February 4, 2007

Huperzine A in Alzheimer's Disease--Phase Two Clinical Trial


The Huperzine A in Alzheimer's Disease clinical trial is currently open and recruiting patients. This is a Phase II clinical trial.



Huperzine A in Alzheimer's Disease-The Clinical Trial

See the trial specification at Clinical Trials.gov

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function

Further study details as provided by National Institute on Aging (NIA).

Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is currently available as a nutraceutical in this country, and is being used by some U.S. clinicians to treat AD. However, there have been no controlled clinical trials outside China assessing its toxicity and efficacy. The present study will evaluate huperzine A in the treatment of AD in a randomized controlled trial of its effect on cognitive function.

The primary aim of this multicenter, double-blind, placebo-controlled therapeutic Phase II trial is to determine whether treatment with huperzine A 200µg twice a day improves cognitive function in individuals with AD. Secondary aims of this study are to: a) determine whether treatment with huperzine A 400µg twice a day improves cognitive function in individuals with AD; b) determine the effect of huperzine A treatment on global clinical status, activities of daily living, and behavior in AD; c) evaluate the tolerability of huperzine A treatment at dosages of 200µg twice a day and 400µg twice a day in AD; and d) determine the relationship between blood cholinesterase activity and cognitive function in individuals with AD treated with huperzine A. A total of 150 participants will be randomly assigned to three groups of equal size. This will allow a comparison of huperzine A 200µg twice a day, huperzine A 400µg twice a day, and placebo. The primary outcome measures will be the change in score on the ADAScog at the 16 week visit. Secondary outcome measures include the ADCS clinical global impression of change (CGIC) (Schneider et al 1997) and activities of daily living (ADL) (Galasko et al 1997) scales, and the Neuropsychiatric Inventory (Cummings 1997). Volunteers must be able to participate in the study for 24 weeks and make 9 visits to the trial site.

At the end of the double-blind study, participants will be invited to continue huperzine A treatment for 6 months in an open-label extension phase. Participants will receive 200µg of huperzine A twice a day for six consecutive months, and will be assessed at 3-month intervals (months 6, 9, and 12, with month 6 assessments coinciding with the final visit of the double-blind phase).

Eligibility

Ages Eligible for Study: 55 Years and above, Genders Eligible for Study: Both CriteriaThe selection process is designed to allow enrollment of all people with AD who are likely to be testable at the conclusion of the study period, and who do not have concurrent medical conditions or medications that might influence cognitive testing or that would increase the risk of treatment. Women and members of minority groups are encouraged to volunteer.

Inclusion Criteria:

NINDS/ADRDA criteria for probable AD.
Mini Mental State Examination between 10 and 24, inclusive.
Stable medical condition for 3 months prior to screening.
Supervision available for administration of study medications.
Study partner to accompany participant to all scheduled visits.
Fluent in English or Spanish.
Age 55 years or older.
Modified Hachinski score equal to or less than 4.
CT or MRI since onset of memory impairment demonstrating absence of clinically significant focal lesion.
Able to complete baseline assessments.
6 years of education, or work history sufficient to exclude mental retardation.
Able to ingest oral medication.
Stable doses of medications for 4 weeks prior to screening.
Physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests.


Exclusion Criteria:

History of active peptic ulcer disease within 1 year of screening.
Clinically significant cardiac arrhythmia.
Resting pulse less than 50.
Active neoplastic (cancer) disease (skin tumors other than melanoma are not excluded; participants with stable prostate cancer may be included at the discretion of the Project Director).
Use of another investigational agent within 2 months of screening.
History of clinically significant stroke.
Current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness and/or immediate confusion after the injury, or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse.
Blindness, deafness, language difficulties or any other disability which may prevent the participant from participating or cooperating in the protocol.
Residence in a skilled nursing facility; but patients in an assisted living facility are acceptable.


Excluded Medications:

Use of cholinesterase inhibitors (galantamine, rivastigmine, donepezil, and tacrine) within 2 months of screening.
Regular use of narcotic analgesics (>2 doses per week) within 4 weeks of screening.
Use of medications with significant central nervous system anticholinergic activity within 2 months of screening (e.g. tricyclic antidepressants, diphenhydramine).
Use of anti-Parkinsonian medications (including Sinemet, amantadine, bromocriptine, pergolide, selegiline) within 2 months of screening.
Participation in any other investigational drug study within 2 months of screening (individuals may not participate in any other drug study while participating in this protocol).
Use of estrogen is allowed if the dose has been stable for 3 months prior to screening.
Use of vitamin E is allowed if the dose has been stable for 3 months prior to screening.
Use of memantine is allowed if the dose has been stable for 3 months prior to screening.

To see a list of availale locations go to Location and Contact Information


Monday, January 22, 2007

Cutting Medicaid drug payments?


"The Bush Administration is proposing “sweeping reductions in payments to pharmacies” to save money for Medicaid, the health program for more than 50 million low-income (and poor) people. God help them, the pharmacies and beneficiaries . . ."

Read the article in its entirety
Cutting Medicaid drug payments?

Sunday, January 21, 2007

Alzheimer's: Understand and control wandering


"One of the questions I am most frequently asked is if I am worried that my mother might wander away from me and get lost. Wandering is one of the more widely known behaviors of people suffering from Alzheimer’s disease. This article from the Mayo Clinic explains this behavior and some of the likely causes and remedies."

Read this article in its entirety Alzheimer's: Understand and control wandering.